TUCSON, Ariz.--(BUSINESS WIRE)--April 27, 2006--AmpliMed today announced the initiation of a Phase I study of benzimate (oral solution) in patients with advanced refractory cancer. The study is designed to establish the safety and tolerability of benzimate and is anticipated to enroll approximately 50 patients at a single clinical center in the United States. Information about the study can be obtained by calling AmpliMed at 520-382-0230.
